L. Ruyatkina

Oral semaglutide: the innovation in type 2 diabetes management

M. Shestakova, G. Galstyan, M. S. Shamkhalova, 2021, Diabetes mellitus.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Raymond L. Forbes, A. Astrup, F. Greenway, 2017, The Lancet.

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board

O. Y. Sukhareva, M. Shestakova, N. Petunina, 2022, Diabetes mellitus.